Articles On Monash IVF Group (ASX:MVF)

Highlights Aluminium and copper edge higher amid broader commodity strength Service Stream secures NBN FTTP rollout contract extension Small caps including Johns Lyng Group and Monash IVF rise early The...

Leading broker Macquarie has tipped an eyewatering 106% upside for ASX All Ords healthcare stock Monash IVF Group Ltd (ASX: MVF).  This comes after the IVF provider's shares suffered a 26% decline yesterday. The ASX All Ords healthcare...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Overseas markets were mixed overnight, with US indices tracking higher, led by Tesla...

Highlights ASX 200 finishes at a new all-time high amid strength in financials and resources Commonwealth Bank closes at record levels alongside gains in Westpac, NAB, and ANZ Lithium and tech names like Pilbara Minerals and...

Highlights ASX 200 lifts as Australian dollar strengthens and global sentiment steadies Monash IVF Group (ASX:MVF) shares fall following disclosure of an embryo error Market awaits outcome of renewed US-China trade negotiati...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

ASX health stocks up 0.57% over past week, while the broader market is up 0.35%  Wave of capital raisings as ASX-listed healthcare firms seek to strengthen their balance sheets Monash IVF’s woes continue with company downgrading FY25 blami...

Yesterday was a forgettable day for Monash IVF Group Ltd (ASX: MVF) shareholders.  The ASX All Ords healthcare company's shares fell 12% after the fertility treatment firm downgraded its guidance for FY 2025. The company now expects it...

Highlights: ASX 200 lifted following RBA’s cash rate cut, led by real estate and tech stocks Financials and consumer discretionary sectors recorded upward momentum Resources and energy shares, especially gold, trailed amid g...

The S&P/ASX 200 Index (ASX: XJO) is having a decent session on Tuesday. In afternoon trade, the benchmark index is up 0.4% to 8,326.8 points. Four ASX shares that have failed to follow the market higher today are listed below. Here's...

With FY 2024 annual reports mostly done and dusted, Macquarie has identified 7 companies sitting on excess franking credits, piles of excess cash, and the capacity to increase their dividend yields. Franking credits are the tax already p...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Monash IVF shares have been under pressure lately.  In April, it was revealed that an Australian woman had unknowingly given birth to a stranger's baby, after her fertility clinic accidentally implanted another woman's embryos into her....

ASX falls 0.82pc, led down by energy and healthcare stocks Gold rises to all-time high at US$3,215 per ounce Oil falls to levels not seen since April 2020, at height of Covid-19 pandemic Despite pulling back on Tuesday, gold prices have h...

ASX heath sector falls 4%, while broader markets down 0.79% for the same period as US tariffs  Monash IVF falls after woman gives birth to a baby that was not hers after mistakenly transferred wrong embryo Imricor starts its European trial...

The S&P/ASX 200 Index (ASX: XJO) recovery has run out of steam on Friday. In afternoon trade, the benchmark index is down 1.45% to 7,596.9 points. Four ASX shares that are falling more than most today are listed below. Here's why they...

After we all took a moment to breath easy yesterday with the S&P/ASX 200 (ASX:XJO) p 4.5% for the day, it appears we’re now back to business as usual with the S&P 500 down 3.7% and the Nasdaq 100 down 4.7%. Yesterday’s momentum was...

It’s up and go time for LTR in the US market All the budget healthcare news – and it’s a short item Prescient launches phase 2a study for a rare blood cancer   The developer of a nasal spray-mist erectile dysfunction (ED) treatment, LTR P...

Reproductive technology developed by Memphasys (ASX:MEM) is proving to be a gamechanger in addressing the men’s side of infertility – which is now understood to cause at least half of all conception issues. The company’s Felix™ System ha...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Morgans analyst Scott Power said this ‘particular reporting season has been one of the worst for a long time’ for ASX healthcare sector ‘Chronic underperformer’ Ramsay Health Care reporting strong performance in its Aussie and UK hospitals...

I believe the ASX small-cap share Monash IVF Group Ltd (ASX: MVF) has a lot of return potential. As its name suggests, it is one of the largest assisted reproduction businesses in Australia. It also has operations related to women's i...

Highlights:  ASX 200 futures signal rebound: Futures up 55 points or 0.69%, indicating the ASX 200 may end its three-day losing streak.  Tech-led rally boosts Wall Street: S&P 500 posted its best session since June, led by gains in...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

This seems like an excellent time to pick up discounted ASX dividend shares while high interest rates have pushed down on the valuations of certain sectors. I'm going to talk about two stocks with share prices under $2. While the share p...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Are you on the lookout for some new additions to your portfolio in December? If you are, it could pay to look at the two ASX 300 shares that brokers have just put buy ratings on. Here's what they are saying about them: Monash IVF Group Ltd...

The ASX healthcare share Monash IVF Group Ltd (ASX: MVF) could be an underrated ASX dividend share, in my eyes. If we look at the chart below, we can see that Monash IVF briefly touched a 52-week low of $1.11 yesterday. In the last...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Control Bionics says it has overcome the “challenges” of the 2023-24 year Ord Minnett identifies the health sector stunners Noxopharm finds a drug manufacturer to kick-start its lupus trial   Health Check is renowned biotech journo Tim Bo...

Greenbox Architecture, a full-service firm that has worked on the likes of Monash IVF's (ASX: MVF) flagship facility and NEXTDC's (ASX: NXT) most recently built Sydney data centre, has been acquired by US-headquartered Woolpert for an undis...

ResMed unveils its 2030 strategy with revenue expected to grow in high single digits for the next five years With a weaker share price Power said Monash IVF could provide a buying opportunity ahead of its AGM in November  ASX health stocks...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

The S&P/ASX 200 Index (ASX: XJO) is having a better day on Thursday. In afternoon trade, the benchmark index is up 0.2% to 7,965.5 points. Four ASX shares that have failed to follow the market higher today are listed below. Here's why...

ASX health stocks rise at time of publishing, in line with broader markets amid mixed reporting season EBOS FY24 result in line with consensus as it looks to fill hole by loss of Chemist Warehouse contract Healius says pathology needs more...

The ASX200 has once again closed higher, up 0.21% at 8,027 points. The IT sector was the strongest performer up 1.9%, followed by Industrials 1.3% and Real Estate 0.8%. Utilities was the poorest performer and finished the day around a...

The All Ordinaries Index (ASX: XAO) is up 0.4% in early afternoon trade, but it's not getting any help from this crashing ASX All Ords stock. The company in question is Monash IVF Group Ltd (ASX: MVF). Before market open this mornin...

Australian shares are set to rise as US stocks gained in afternoon trade, buoyed by revisions to jobs data that largely met expectations. This development reinforces the view that the US labor market is cooling, increasing the likelihood th...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

It's looking like this Tuesday will be another positive day for the Australian share market and most ASX All Ords shares. At the time of writing, the All Ordinaries Index (ASX: XAO) has risen by a healthy 0.4%, leaving the index at just ove...

  US markets opened in positive territory before Fed rates commentary and a pop in oil prices spooked traders and triggered an afternoon sell off. The Dow Jones finished the day down 1.4 per cent, the S&P500 closed down 1.2 per cent aft...

The ASX 200 lifted modestly by +0.2% on Thursday as gains in Tech and Industrial stocks were offset by losses in Energy.  Local traders brushed out dovish comments from Fed Chair Jerome Powell last night. Appearing before Congress, Powell r...

  The S&P 500 rose Wednesday as investors attempted to turn a corner following back-to-back losing sessions on Wall Street. The S&P 500 added 0.51 per cent to 5,104.76, while the Nasdaq Composite gained 0.58 per cent to 16,031.54. T...

Note: Figures recorded at 7:40am AEDT. Updated figures and a video recording will be available at 9am AEDT. The S&P 500 rose Wednesday as investors attempted to turn a corner following back-to-back losing sessions on Wall Street. The br...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

QBE Insurance elevated to S&P/ASX 20 as gold miner Newmont removed Flight Centre and Pro Medicus both make the S&P/ASX 100 in March rebalance Several tech companies make benchmark S&P/ASX 200 but not so good for resources  Mar...